Oragenics Inc.

Snapshot

Oragenics is a clinical-stage biotech with zero revenue, a $9.8M net loss in FY 2025, and only $3.9M of cash on hand. Management says that cash funds operations only through the end of 2026, and Signal8 models roughly 1.2 months of runway.

What's Happening Right Now

• Wed 16th Sep '26 · Conference presentation: Oragenics' Chief Medical Officer presented on the ONP-002 intranasal concussion platform at the IPAC-RS 2026 Nasal Innovation Forum on September 17, 2026; the company says this was a visibility event with no new trial data or financial figures.
• Fri 28th Aug '26 · Listing deficiency: On August 26, 2026 Oragenics received a NYSE American deficiency letter for insufficient stockholders' equity, with 45 days to submit a compliance plan and until February 25, 2028 to regain compliance; separately the company reported 9 patients dosed in its Phase IIa ONP-002 trial and is reviewing FDA Type B meeting feedback ahead of a planned year-end IND submission.
• Thu 13th Aug '26 · Earnings/Going-concern: Oragenics' 10-Q for the period ended June 30, 2026 showed a $4.7M first-half net loss on zero revenue, cash of $3.9M expected to fund operations only through December 31, 2026, and going-concern doubt carried forward from the FY2025 audit; dilution overhang grew after the Series H conversion price was cut to $1.00 with no floor.
• Wed 12th Aug '26 · Price action: Shares traded modestly higher in mid-August 2026 trading, touching $0.5490 before settling near $0.5489 on light volume.
• Tue 31st Mar '26 · ATM sale: Sold $79K net / 85K shares through its at-the-market program, as stated for Mar 1, 2026 to Mar 31, 2026.
• Fri 20th Mar '26 · Registration: Registered $100.00M of securities for sale on Form S-3.
• Fri 13th Mar '26 · Offering: Closed an offering. Proceeds are not disclosed in the filings reviewed.